Fortis Therapeutics is pioneering the development of targeted therapies that focus on CD46, a protein that is overexpressed in certain cancer types. Their proprietary approach utilizes precision therapies to deliver treatments specifically to CD46 proteins, minimizing damage to normal tissues. This method represents a significant shift from traditional cancer treatments, which often indiscriminately affect both healthy and cancerous cells. By concentrating on a specific target, Fortis aims to enhance treatment efficacy while reducing side effects, thereby transforming patient outcomes in oncology.

One of the key products in Fortis's pipeline is FOR46, an antibody-drug conjugate (ADC) designed for late-stage prostate cancer and multiple myeloma. FOR46 is engineered to deliver a potent therapeutic payload directly to cancer cells expressing high levels of CD46, particularly in cases resistant to standard treatments like abiraterone or enzalutamide. The company is actively conducting clinical trials to evaluate the safety and effectiveness of FOR46 in patients with metastatic castration-resistant prostate cancer and relapsed multiple myeloma, demonstrating their commitment to advancing innovative cancer therapies that leverage the unique characteristics of CD46.

United States

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody drug conjugate therapies against CD46 for the treatment of late-stage prostate cancer and multiple myeloma.

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

Fortis Therapeutics

Company Details